Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

The stock is down 42% from its June 2024 high, raising questions about whether it’s an attractive entry point given ... a sad trend as the global diabetes patients have quadrupled from 1990 ...

Millions of people have diabetes ... on 240 patients. Researchers hope to have the trials complete and the system perfected in four years. Smartphones may soon be able to add one more entry ...

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of ...

Sublingual Allergy Immunotherapy Market The rising of allergic diseases, such as allergic rhinitis and asthma, is a factor driving the grow ...

For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the ... that are ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

Objective People living with diabetes need and deserve ... and stated it clearly in the consent form; no one did so. Field notes were compiled by all interviewers after data collection. Overall, 21 ...

The global Enteral Formula industry has an estimated market valuation of USD 8.0 billion by 2024 and is projected to grow at ...

In all groups patients with a history of ocular comorbidities, previous ocular surgery, or diabetes ... form of optical correction, its cost, and about their knowledge of and interest in laser ...

SARS-CoV-2 has wreaked havoc globally and has claimed innumerable lives all over the world. Apart from the characteristic respiratory illness, this disease has been associated with florid ...